X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA SANOFI INDIA PLETHICO PHARMA/
SANOFI INDIA
 
P/E (TTM) x -1.1 38.9 - View Chart
P/BV x 0.0 8.4 0.2% View Chart
Dividend Yield % 0.0 1.1 -  

Financials

 PLETHICO PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
SANOFI INDIA
Dec-16
PLETHICO PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs3954,560 8.7%   
Low Rs314,400 0.7%   
Sales per share (Unadj.) Rs604.41,028.5 58.8%  
Earnings per share (Unadj.) Rs32.5129.0 25.2%  
Cash flow per share (Unadj.) Rs51.3186.0 27.6%  
Dividends per share (Unadj.) Rs068.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs473.6753.6 62.8%  
Shares outstanding (eoy) m34.0823.03 148.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.44.4 8.1%   
Avg P/E ratio x6.634.7 18.9%  
P/CF ratio (eoy) x4.224.1 17.2%  
Price / Book Value ratio x0.55.9 7.6%  
Dividend payout %052.7 0.0%   
Avg Mkt Cap Rs m7,262103,174 7.0%   
No. of employees `000NA3.6 0.0%   
Total wages/salary Rs m1,5963,592 44.4%   
Avg. sales/employee Rs ThNM6,537.7-  
Avg. wages/employee Rs ThNM991.4-  
Avg. net profit/employee Rs ThNM819.8-  
INCOME DATA
Net Sales Rs m20,59823,686 87.0%  
Other income Rs m386708 54.6%   
Total revenues Rs m20,98424,394 86.0%   
Gross profit Rs m2,8185,281 53.4%  
Depreciation Rs m6421,313 48.9%   
Interest Rs m1,59315 10,621.3%   
Profit before tax Rs m9694,661 20.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1381,691 -8.2%   
Profit after tax Rs m1,1072,970 37.3%  
Gross profit margin %13.722.3 61.4%  
Effective tax rate %-14.336.3 -39.4%   
Net profit margin %5.412.5 42.9%  
BALANCE SHEET DATA
Current assets Rs m18,87715,673 120.4%   
Current liabilities Rs m11,8966,678 178.1%   
Net working cap to sales %33.938.0 89.2%  
Current ratio x1.62.3 67.6%  
Inventory Days Days3676 47.3%  
Debtors Days Days19822 886.6%  
Net fixed assets Rs m9,8618,098 121.8%   
Share capital Rs m341230 147.9%   
"Free" reserves Rs m12,33117,088 72.2%   
Net worth Rs m16,13917,356 93.0%   
Long term debt Rs m4,7060-   
Total assets Rs m33,14625,400 130.5%  
Interest coverage x1.6311.7 0.5%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.60.9 66.6%   
Return on assets %8.111.8 69.3%  
Return on equity %6.917.1 40.1%  
Return on capital %12.326.9 45.6%  
Exports to sales %21.424.5 87.3%   
Imports to sales %15.228.0 54.4%   
Exports (fob) Rs m4,4025,801 75.9%   
Imports (cif) Rs m3,1366,627 47.3%   
Fx inflow Rs m4,4027,145 61.6%   
Fx outflow Rs m3,1846,846 46.5%   
Net fx Rs m1,219299 407.5%   
CASH FLOW
From Operations Rs m2,4373,226 75.6%  
From Investments Rs m-6,265-1,555 402.9%  
From Financial Activity Rs m2,490-1,818 -137.0%  
Net Cashflow Rs m-1,337-147 909.6%  

Share Holding

Indian Promoters % 82.7 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 4.3 14.4 29.9%  
FIIs % 5.5 14.6 37.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 10.5 71.4%  
Shareholders   10,665 15,184 70.2%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   SHASUN PHARMA  DR. REDDYS LAB  ABBOTT INDIA  UNICHEM LAB  MERCK LTD  

Compare PLETHICO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY18); Net Profit Up 37.5% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, SANOFI INDIA has posted a net profit of Rs 825 m (up 37.5% YoY). Sales on the other hand came in at Rs 6 bn (up 11.7% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA - DR. DATSONS LABS COMPARISON

COMPARE PLETHICO PHARMA WITH

MARKET STATS